Johnson & Johnson Prostate Cancer Drug Shrinks Tumors in Early-Stage Trial
Johnson & Johnson reported that its prostate cancer drug shrank tumors in an early-stage trial.
Johnson & Johnson reported that its prostate cancer drug shrank tumors in an early-stage trial.